Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tegaserod. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 known ✓ | Q13639 | 1/20 | 0.61 |
| ▸ | HTR1A | P08908 | 6/20 | 0.63 |
| ▸ | HTR2C | P28335 | 5/20 | 0.63 |
| ▸ | HTR2B | P41595 | 3/20 | 0.63 |
| ▸ | HTR1D | P28221 | 3/20 | 0.63 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.63 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.63 |
| ▸ | DRD2 | P14416 | 2/20 | 0.63 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.63 |
| ▸ | DRD4 | P21917 | 2/20 | 0.63 |
| ▸ | HTR2A | P28223 | 2/20 | 0.63 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.63 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.63 |
| ▸ | DRD3 | P35462 | 2/20 | 0.63 |
| ▸ | HTR3A | P46098 | 2/20 | 0.63 |
| ▸ | HTR5A | P47898 | 2/20 | 0.63 |
| ▸ | HTR6 | P50406 | 2/20 | 0.63 |
| ▸ | USP2 | O75604 | 1/20 | 0.63 |
| ▸ | DRD5 | P21918 | 1/20 | 0.63 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tegaserod SCHEMBL4636798 | 0.96 | HTR1A (0.61) | HTR1AHTR2CHTR2BHTR1DADRB1 | |
| Tegaserod SCHEMBL3892146 | 0.96 | HTR1A (0.63) | HTR1AHTR2CHTR2BHTR1DADRB1 | |
| Tegaserod SCHEMBL1042179 | 0.95 | HTR1A (0.70) | HTR1AHTR2CHTR2BHTR1DADRB1 | |
| Tegaserod SCHEMBL4636808 | 0.95 | HTR1A (0.62) | HTR1AHTR2CHTR2BHTR1DADRB1 | |
| Tegaserod SCHEMBL27215 | 0.95 | HTR1A (0.70) | HTR1AHTR2CHTR2BHTR1DADRB1 | |
| Tegaserod SCHEMBL4637068 | 0.95 | HTR1A (0.62) | HTR1AHTR2CHTR2BHTR1DADRB1 | |
| Tegaserod SCHEMBL4158807 | 0.95 | HTR1A (0.70) | HTR1AHTR2CHTR2BHTR1DADRB1 | |
| Tegaserod SCHEMBL20362149 | 0.95 | HTR1A (0.70) | HTR1AHTR2CHTR2BHTR1DADRB1 | |
| Tegaserod SCHEMBL3893820 | 0.95 | HTR1A (0.70) | HTR1AHTR2CHTR2BHTR1DADRB1 | |
| Tegaserod SCHEMBL774764 | 0.95 | HTR1A (0.67) | HTR1AHTR2CHTR2BHTR1DADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008077871-A1 | SALTS OF TEGASEROD | NOVARTIS AG (CH) | 2008-07-03 | — | — | WO | claimed |
| EP-1939176-A1 | Salts of Tegaserod | Novartis AG (CH) | 2008-07-02 | — | — | EP | claimed |
| WO-2007126889-A1 | PREPARATION OF TEGASEROD ACETATE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-11-08 | — | — | WO | claimed |
| EP-1771414-A1 | AMORPHOUS TEGASEROD MALEATE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-04-11 | — | — | EP | claimed |
| EP-1740539-A2 | PREPARATION OF TEGASEROD AND TEGASEROD MALEATE | Teva Pharmaceutical Industries Ltd (IL) | 2007-01-10 | — | — | EP | claimed |
| US-20060258633-A1 | Amorphous tegaserod maleate | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-11-16 | — | — | US | claimed |
| WO-2006096802-A1 | AMORPHOUS TEGASEROD MALEATE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-09-14 | — | — | WO | claimed |
| US-20060106086-A1 | Preparation of tegaserod and tegaserod maleate | TEVA PHARMACEUTICALS USA, INC. | 2006-05-18 | — | — | US | claimed |
| EP-1594493-A2 | POLYMORPHIC FORMS OF TEGASEROD BASE AND SALTS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2005-11-16 | — | — | EP | claimed |
| WO-2005105740-A2 | PREPARATION OF TEGASEROD AND TEGASEROD MALEATE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2005-11-10 | — | — | WO | claimed |
| US-20050165085-A1 | Polymorphic forms of tegaserod base and salts thereof | TEVA PHARMACEUTICALS USA INC. | 2005-07-28 | — | — | US | claimed |
| WO-2005058819-A2 | POLYMORPHIC FORMS OF TEGASEROD BASE AND SALTS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2005-06-30 | — | — | WO | claimed |
| WO-2010015794-A1 | NOVEL POLYMORPHIC FORMS OF TEGASEROD | GENERICS [UK] LIMITED (GB) | 2010-02-11 | — | — | WO | disclosed |
| WO-2008077871-A1 | SALTS OF TEGASEROD | NOVARTIS AG (CH) | 2008-07-03 | — | — | WO | disclosed |
| EP-1939176-A1 | Salts of Tegaserod | Novartis AG (CH) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007126889-A1 | PREPARATION OF TEGASEROD ACETATE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-11-08 | — | — | WO | disclosed |
| EP-1594493-A2 | POLYMORPHIC FORMS OF TEGASEROD BASE AND SALTS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2005-11-16 | — | — | EP | disclosed |
| WO-2005105740-A2 | PREPARATION OF TEGASEROD AND TEGASEROD MALEATE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2005-11-10 | — | — | WO | disclosed |
| US-20050165085-A1 | Polymorphic forms of tegaserod base and salts thereof | TEVA PHARMACEUTICALS USA INC. | 2005-07-28 | — | — | US | disclosed |
| WO-2005058819-A2 | POLYMORPHIC FORMS OF TEGASEROD BASE AND SALTS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258633-A1 | Amorphous tegaserod maleate | SI, MLNR, SLC10A2 | HTR4 116/4885HTR1A 101/4885HTR2C 574/4885 |
| US-20060106086-A1 | Preparation of tegaserod and tegaserod maleate | MLNR, SLC10A2, MLN | HTR4 418/4885HTR1A 229/4885HTR2C 1232/4885 |
| US-20050165085-A1 | Polymorphic forms of tegaserod base and salts thereof | MLNR, SLC10A2, UGT1A3 | HTR4 286/4885HTR1A 280/4885HTR2C 848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.